PharmaVigilant Launches PaySite 2.0, A New Site Payment System
PharmaVigilant
today unveiled PaySite 2.0, a new Site Payment System that provides a complete dashboard to the sponsor, enabling them to program site payments based upon performance and individual site contracts. With PaySite, sponsors can determine payments made both graphically and within defined reports, and generate site letters defining the payouts and the criteria associated with the payment. Combined, this functionality streamlines the site payment process, improving the relationship between the sponsor and the site.
PaySite has no limitations regarding combinations; complex compensation programs can be easily defined and implemented in any currency. Information can be exported in sponsors’ accounting systems to further streamline the payment process.
“One of the keys to enhancing site/sponsor relationships is paying sites on time. As sponsors’ accounting processes elongate in complexity and time, site payments get extended, creating stress on the relationship,” said James DeSanti, founder and chief executive officer, PharmaVigilant. “PaySite reduces the time upfront by creating payment reports on-demand, or with manual overrides when required.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
